Jaap Bremer

T: +31 70 376 06 25
E: jaap.bremer@barentskrans.nl
View Jaap Bremer on LinkedIn

Jaap’s practice focuses on Intellectual Property litigation, in particular with respect to patents, trademarks and advertising. Jaap has extensive experience in infringement and invalidity litigation, as well as in parallel import, anti-counterfeiting and customs enforcement matters, particularly for clients in the pharma & life sciences, food & beverage and consumer products industries. He also regularly advises clients in non-contentious matters, including negotiation and drafting of licence and coexistence agreements. Jaap is internationally recognized as a specialist in both patent law and trademark and copyright law. In Chambers 2020, he was the only lawyer in the Netherlands to be ranked in both categories.

Selected directory listings

“Jaap Bremer is a top quality advocate and legal practitioner, adept at rapidly getting to grips with complex technologies.” – Legal 500, 2021

“Jaap Bremer is a standout trade mark lawyer, combining legal knowledge with a practical, commercial application and also Jaap Bremer: hands-on, practical advice combined with an open mind to handle matters, leading to solutions that the business can always work with. Experienced litigator and negotiator.’”Legal 500, 2021

“Jaap Bremer is active on both trade mark and patent disputes. His adroit manner of communication is underlined by clients, one informing of his ability to quickly grasp the essence of a case, which he can then explain in easy-to-understand language accurately to the client and the judges.”Chambers Europe, 2021

“Department head Bremer’s personable approach, eye for detail and deep patent knowledge are appreciated by those seeking to defend intricate inventions.“- IAM Patents 1000, 2021

“Digging into the details of cases and providing rock-solid support to Mylan and many others, Jaap Bremer has unrivalled knowledge and expertise in the pharmaceutical area and is one of the best patent litigators in the country.” IAM Patent 1000, 2020

 

Professional activities

  • Member of Editorial Board EPLAW Patent Blog
  • Active member of the International Trademark Association (INTA)
  • Member of various professional associations, including EPLAW, PTMG, LES, BMM, VFenR, VvRr and MARQUES
  • Member of Vereniging Intellectuele Eigendom Proces Advocaten (VIEPA)

Recently from this specialist

Pharma update – 17 August 2021 | Provisions judge denies preliminary order to carve out indications from marketing authorisation adalimumab biosimilar

In his decision of 16 July 2021 (published 5 August 2021) the Provisions Judge of the District Court of Amsterdam denied a preliminary order claimed by AbbVie Biotechnology Ltd (“AbbVie”) against Alvotech HF, Alvotech Swiss AG and Stada Arzneimittel AG (“Stada”) (collectively: “Alvotech et al.”) to carve-out AbbVie’s patented indications prior to launching their biosimilar
Read more ›

Telecoms update | District Court rejects infringement claim

On 30 December 2020 (published 13 January 2021), the District Court of The Hague (“the Court”) rendered a judgment in final relief proceedings initiated by Adaptive Spectrum and Signal Alignment, Incorporated (“ASSIA”) against Koninklijke KPN N.V., Telfort Zakelijk B.V., XS4ALL Internet B.V., KPN B.V. (collectively “KPN”) and Nokia Solutions and Networks Nederland B.V. (“Nokia”) regarding
Read more ›

Pharma update | AstraZeneca ordered to compensate damage health insurer Menzis for enforcing invalid patent

In a groundbreaking judgment of 14 October 2020, the District Court of The Hague ruled that AstraZeneca AB (‘AstraZeneca’) must compensate health insurer Menzis Zorgverzekeraar NV (‘Menzis’) for having enforced a patent that was later invalidated. AstraZeneca owned European patent EP 0 907 364 (“EP 364”) for a sustained-release (XR) formulation of quetiapine, an active
Read more ›
More from this specialist